5 results about "FGF1" patented technology

The present invention provides fusion proteins comprising a fibroblast growth factor 1 (FGF1) peptide and a fibroblast growth factor 21 (FGF21) peptide. Pharmaceutical compositions and wound dressings comprising the fusion proteins, polynucleotides encoding the fusion proteins, and methods of using the fusion proteins to treat a condition in a subject are also provided.

The present application relates to the application of Hu sheep FGF1 gene and its coded protein, and belongs to the field of biotechnology. The application of Hu sheep FGF1 gene and its coded protein in regulating the level of oxidative stress, cell apoptosis or cell proliferation of ovary granulosa cells. The present application first systematically identifies the CDS and protein sequence of sheep FGF1 gene, and analyzes its physical and chemical properties, post-translational modification sites, secondary and tertiary structures and systematic evolution relationship, which provides a molecular basis for revealing the role of the gene in oxidative stress and cell fate regulation. In addition, the disclosed sequence information and variation data are helpful for evaluating population genetic diversity, and have important scientific value for the protection, development and evolution research of animal genetic resources.

This invention belongs to the field of aquaculture biotechnology and discloses the application of a grass carp FGF1 recombinant protein in the preparation of products against Aeromonas hydrophila infection. The amino acid sequence of the recombinant protein is shown in SEQ ID NO:2. This invention is the first to discover that this known protein effectively reduces the pathogen load in tissues such as the liver and spleen by repairing the intestinal mucosal physical barrier (significantly increasing the number of intestinal goblet cells, promoting epithelial cell proliferation, and inhibiting apoptosis) and strengthening the immune barrier (upregulating key antibacterial factors such as IL-22, MUC2, Spla2, and HB-EGFa), and significantly increases the 14-day survival rate of grass carp infected with Aeromonas hydrophila from 10% to 56.67%. This invention overcomes the shortcomings of existing technologies that rely solely on in vitro sterilization or are limited to non-infectious factors, providing a green and efficient biological product solution based on host barrier repair for bacterial diseases in grass carp.

The application discloses a fusion FGF1 protein sequence which does not affect the heparin binding capacity and a corresponding DNA sequence, and belongs to the technical field of biology.The nucleotide sequence of the fusion protein FGF1-Pt provided by the application is shown in Seq ID No.10, and the amino acid sequence is shown in Seq ID No.5.The application places Pt at the C-terminal of FGF1, has the best heparin binding capacity without adding a linking peptide, has the highest expression amount of Escherichia coli, and provides materials for the function research of the membrane penetrating peptide of Pt and how Pt affects the spatial structure and activity of FGF1.

The disclosure provides for the culture media particularly suitable to culture primary ostrich PGCs. The culture media contain specific growth factors and compounds that provide support for the growth and proliferation of ostrich PGCs. In certain embodiments, the culture media contain a basal culture medium and β-mercaptoethanol, cholesterol, FGF1, FGF2, BMP4, and IGF1. In some embodiments, the basal culture medium contains knock-out DMEM, B27 Supplement, MEM-MEAA, L-alanyl-L-glutamine dipeptide, cytidine, guanosine, uridine, adenosine, thymidine, sodium pyruvate, ovalbumin, sodium heparin, calcium chloride, ovotransferrin, and an antibiotic. The disclosure also includes methods and kits for producing such media as well as methods of culturing cells.